Skip to main content
Premium Trial:

Request an Annual Quote

IntegraGen Licenses Biomarkers to Develop Dx for Liver Cancer

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – French molecular diagnostics outfit IntegraGen, the French National Institute for Health and Medical Research (INSERM), and its technology transfer subsidiary, INSERM Transfert, announced on Tuesday an agreement granting IntegraGen an exclusive worldwide option to license a portfolio of biomarkers for hepatocellular carcinoma.

IntegraGen will use the biomarkers to develop genetic diagnostics for the personalized treatment of the disease, which affects more than 70,000 people annually in Europe and the US. The biomarkers were discovered and developed by Jessica Zucman-Rossi, a clinical researcher at the Descartes University of Paris/Georges Pompidou European Hospital, and director of the INSERM U674 research unit.

Terms of the agreement were not disclosed.

In a statement, IntegraGen CEO Bernard Courtieu said that his firm plans to validate tools developed under the agreement within the next two years under clinical conditions. Fabien Calvo, director of INSERM's ITMO cancer institute, added that the methods developed by Zucman-Rossi will enable patient stratification.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.